166 related articles for article (PubMed ID: 37184681)
1. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M; Koçak MZ; Dinç G; Genç TB; Çağlayan M; Uğraklı S; Hendem E; Er MM; Çağlayan D; Eryılmaz MK; Araz M; Geredeli Ç; Tatlı AM; Eren OÖ; Artaç M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9183-9189. PubMed ID: 37184681
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E; Dalban C; Colomba E; Derosa L; Alves Costa Silva C; Negrier S; Chevreau C; Gravis G; Oudard S; Laguerre B; Barthelemy P; Goupil MG; Geoffrois L; Rolland F; Thiery-Vuillemin A; Joly F; Ladoire S; Tantot F; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Oct; 20(5):488-494. PubMed ID: 35977881
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
4. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
5. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma.
Mollica V; Santoni M; Matrana MR; Basso U; De Giorgi U; Rizzo A; Maruzzo M; Marchetti A; Rosellini M; Bleve S; Maslov D; Tawagi K; Philon E; Blake Z; Massari F
Target Oncol; 2022 Jan; 17(1):61-68. PubMed ID: 34894318
[TBL] [Abstract][Full Text] [Related]
6. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Lalani AA; McKay RR; Lin X; Simantov R; Kaymakcalan MD; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):724-732. PubMed ID: 28645482
[TBL] [Abstract][Full Text] [Related]
8. Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab.
Catalano M; Rebuzzi SE; Maruzzo M; De Giorgi U; Buti S; Galli L; Fornarini G; Zucali PA; Procopio G; Chiellino S; Milella M; Catalano F; Pipitone S; Ricotta R; Sorarù M; Mollica V; Tudini M; Fratino L; Prati V; Caffo O; Atzori F; Morelli F; Prati G; Nolè F; Vignani F; Cavo A; Di Napoli M; Malgeri A; Naglieri E; Signori A; Banna GL; Rescigno P; Antonuzzo L; Roviello G
JAMA Netw Open; 2023 Nov; 6(11):e2345185. PubMed ID: 38010650
[TBL] [Abstract][Full Text] [Related]
9. The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma.
Buti S; Tommasi C; Scartabellati G; De Giorgi U; Brighi N; Rebuzzi SE; Puglisi S; Caffo O; Kinspergher S; Mennitto A; Cattrini C; Santoni M; Verzoni E; Rametta A; Stellato M; Malgeri A; Roviello G; de Filippo M; Cortellini A; Bersanelli M
Anticancer Drugs; 2023 Jan; 34(1):178-186. PubMed ID: 36539370
[TBL] [Abstract][Full Text] [Related]
10. Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma.
Santoni M; Massari F; Matrana MR; Basso U; De Giorgi U; Aurilio G; Buti S; Incorvaia L; Rizzo M; Martignetti A; Maslov D; Tawagi K; Philon E; Blake Z; Porta C; Battelli N
Eur J Cancer; 2022 Sep; 172():191-198. PubMed ID: 35780525
[TBL] [Abstract][Full Text] [Related]
11. The effect of concomitant use of proton pump inhibitors with CDK 4/6 inhibitors on survival in metastatic breast cancer.
Çağlayan D; Koçak MZ; Geredeli Ç; Tatlı AM; Göksu SS; Eryılmaz MK; Araz M; Artaç M
Eur J Clin Pharmacol; 2023 Feb; 79(2):243-248. PubMed ID: 36520173
[TBL] [Abstract][Full Text] [Related]
12. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
14. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
[TBL] [Abstract][Full Text] [Related]
15. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study.
Eser K; Önder AH; Sezer E; Çil T; İnal A; Öztürk B; Erçolak V; Duman BB; Çelik H; Köşeci T; Kesen O
BMC Cancer; 2022 May; 22(1):516. PubMed ID: 35525929
[TBL] [Abstract][Full Text] [Related]
17. Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer.
Lee JE; Kwon SH; Kwon S; Jung HI; Nam JH; Lee EK
JAMA Netw Open; 2023 Jul; 6(7):e2324852. PubMed ID: 37477917
[TBL] [Abstract][Full Text] [Related]
18. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
19. Effect of Concomitant Use of Proton Pump Inhibitors on Immunotherapy Clinical Response in Advanced Cancer Patients: Real-Life Setting.
Cantarelli L; Gutiérrez Nicolás F; García Gil S; Morales Barrios JA; Oramas Rodriguez J; Nazco Casariego GJ
J Immunother; 2023 Nov; ():. PubMed ID: 37937583
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
